

InteliCare Holdings Ltd ABN 84 622 484 397

ASX Code ICR

### **Corporate Directory**

Non-Executive Chair **Dr Neale Fong** 

Non-Executive Director **Mr Greg Leach** 

Non-Executive Director Mr Cam Ansell

Company Secretary
Mr Neil Hackett

Chief Executive Officer
Mr Daniel Pilbrow

Issued Shares 236,188,134

Unlisted Options (including Perf Rights) 51,273,077

Listed Options 74,824,568

### **Company Details**

Email

investors@intelicare.com.au Website

www.intelicare.com.au

## Registered & Principal Office

Level 1, 299 Vincent St Leederville WA 6001

# InteliCare to Raise \$2 million via Two Tranche Placement to Accelerate Growth

#### **HIGHLIGHTS**

- ICR has received firm commitments to raise \$2 million via a twotranche placement at 0.8 cents per new share with a 1:3 freeattaching option exercisable at 2 cents with an expiry date 3 years from date of issue;
- Commitments have been received from both existing and new institutional and sophisticated professional investors
- Under Tranche 1, 56,175,162 fully paid ordinary shares will be issued immediately under ICR's existing LR7.1 & 7.1A capacity raising approximately \$450k;
- Under Tranche 2, 193,824,838 fully paid ordinary shares and 83,333,333 options will be issued, subject to shareholder approvals at an upcoming EGM, raising the balance of approximately \$1.55m; and
- Proceeds will support the Company's growth strategy allowing for ICR to accelerate deployments for potential new customers in the pipeline and provide working capital to support pilot programs.

InteliCare Holdings Ltd ("ICR" or the "Company") (ASX: ICR), an Australian Software-as-a-Service (SaaS) technology company commercialising its proprietary AI driven InteliCare platform (InteliCare) in the aged care, disability and health sectors is pleased to announce it has received firm commitments to raise \$2 million via a two-tranche private placement (Placement) to institutional and sophisticated professional investors.

Daniel Pilbrow, Chief Executive Officer, says: "We are grateful for the continued support of the Company by its existing shareholders and welcome new shareholders. The extra funds received from this Placement will be used to push further commercial agreements with key groups in the Company's sales pipeline.

I am excited for what the next 18 months has in store for the Company and its prospects. ICR has demonstrated its ability to deliver on its B2B business model with the recent deployment in Hardi Aged Care facilities — we will use this validation to continue to build the increasing market interest in the Aldriven InteliCare platform, leveraging the expanding capabilities of our offering to assist aged-care, healthcare and disability support providers in delivering high quality care and great outcomes for individuals."

Tranche 1 of the Placement will be completed under the Company's ASX LR 7.1 and 7.1A placement capacity raising approximately \$450k via the issue of 56,175,162 new fully paid ordinary shares at 0.8 cents per share. Tranche 2 of the Placement will be completed, subject to shareholder approval at an upcoming EGM to approve the issue of 193,824,838 new fully paid ordinary

shares raising the balance of approximately \$1.55m at 0.8 cents per share. The issue of the 1:3 free-attaching options, exercisable at 2.0 cents and with a three-year expiry, which form part of the terms of this capital raising will also be subject to a shareholder approval at the same aforementioned upcoming EGM. The Placement was completed with professional and sophisticated investors within section 708(8) and section 708(11) of the Corporations Act (Cth).

As part of the Placement, Non-Executive Director and co-founder Greg Leach has committed to subscribing for \$100,000 under the Placement terms. In order to complete his investment shareholder approval will be sought at an upcoming EGM under ASX LR 10.11 for the issue of 12.5 million new shares and 4,166,667 new options.

Clarity Capital Advisors Pty Ltd acted as lead manager to the capital raising and received a 6% capital raising fee and 30 million options on the same terms as the free-attaching options in the Placement. These 30 million options are subject to shareholder approval at the upcoming EGM being held to approve Tranche 2 of the Placement.

This announcement is designed to lift the current trading halt in InteliCare's securities.

### **ENDS**

This announcement is approved for release by the Board of InteliCare Holdings Limited.

For more information regarding InteliCare, visit www.intelicare.com.au.

Contact and Authorised for Release to the ASX

Daniel Pilbrow, Chief Executive Officer, InteliCare Holdings Ltd, +61 1300 001 145, investors@intelicare.com.au

### **About Intelicare Holdings Limited**

InteliCare is an Australian technology company that has commercialised a predictive analytics hardware and software system for use in the aged care and health industries. InteliCare believes Australians deserve to age with dignity and through its business-to-business (B2B) and business-to-consumer (B2C) solutions built on its proprietary internet of things (IOT) platform utilising smart sensors and artificial intelligence (AI), InteliCare aims to enable people to stay in their own homes for longer while empowering healthcare providers to deliver higher quality, more efficient services.

